HER2 Biology, Detection, and Clinical Implications

被引:15
作者
Gutierrez, Carolina [1 ]
Schiff, Rachel [2 ]
机构
[1] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[2] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
关键词
IN-SITU HYBRIDIZATION; METASTATIC BREAST-CANCER; ESTROGEN-RECEPTOR; ADJUVANT CHEMOTHERAPY; GUIDELINE RECOMMENDATIONS; MOLECULAR PORTRAITS; GENE AMPLIFICATION; PROTEIN EXPRESSION; AMERICAN-SOCIETY; TRASTUZUMAB;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell with potent proliferative and antiapoptosis signals and it is the major driver of tumor development and progression for this subset of breast cancer. When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target. Objectives.-To review the basic biology of the HER2 signaling network, to discuss various approved methods for its detection in clinical specimens, and to describe the impressive results of therapies targeting HER2. Data Sources.-Selected literature searchable on PubMed as well as older studies revealed by the literature review were reviewed. Conclusion.-HER2 is an important member of a complex signaling network and when gene amplified, it results in an aggressive subtype of breast cancer. Patients with tumors found to overexpress HER2 protein or to be amplified for the gene are candidates for therapy that significantly reduces mortality. (Arch Pathol Lab Med. 2011;135:55-62)
引用
收藏
页码:55 / 62
页数:8
相关论文
共 77 条
[1]   OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
MOLINA, R ;
TANDON, AK ;
SCHNITT, SJ ;
GILCHRIST, KW ;
OSBORNE, CK ;
TORMEY, DC ;
MCGUIRE, WL .
HUMAN PATHOLOGY, 1992, 23 (09) :974-979
[2]  
[Anonymous], BREAST CANC RES T S1
[3]   Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy [J].
Arpino, Grazia ;
Gutierrez, Carolina ;
Weiss, Heidi ;
Rimawi, Mothaffar ;
Massarweh, Suleiman ;
Bharwani, Lavina ;
De Placido, Sabino ;
Osborne, C. Kent ;
Schiff, Rachel .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :694-705
[4]  
Barnes Christopher J, 2004, Cancer Treat Res, V119, P1
[5]   The epidermal growth factor receptor family [J].
Bazley, LA ;
Gullick, WJ .
ENDOCRINE-RELATED CANCER, 2005, 12 :S17-S27
[6]   Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].
Blackwell, Kimberly L. ;
Burstein, Harold J. ;
Storniolo, Anna Maria ;
Rugo, Hope ;
Sledge, George ;
Koehler, Maria ;
Ellis, Catherine ;
Casey, Michelle ;
Vukelja, Svetislava ;
Bischoff, Joachim ;
Baselga, Jose ;
O'Shaughnessy, Joyce .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130
[7]   HER2 expression in breast cancer primary tumours and corresponding metastases.: Original data and literature review [J].
Carlsson, J ;
Nordgren, H ;
Sjöström, J ;
Wester, K ;
Villman, K ;
Bengtsson, NO ;
Ostenstad, B ;
Lundqvist, H ;
Blomqvist, C .
BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2344-2348
[8]   EGF-ERBB signalling: towards the systems level [J].
Citri, Ami ;
Yarden, Yosef .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (07) :505-516
[9]  
Clarke M, 1998, LANCET, V351, P1451
[10]   Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH [J].
Desmedt, Christine ;
Sperinde, Jeff ;
Piette, Fanny ;
Huang, Weidong ;
Jin, Xueguang ;
Tan, Yuping ;
Durbecq, Virginie ;
Larsimont, Denis ;
Giuliani, Rosa ;
Chappey, Colombe ;
Buyse, Marc ;
Winslow, John ;
Piccart, Martine ;
Sotiriou, Christos ;
Petropoulos, Christos ;
Bates, Michael .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2009, 18 (01) :22-29